Orexigen Therapeutics, Inc. (NASDAQ:OREX) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $5.82, down by -3.64%, with a volume of 2,193,011 shares against an average volume for the last 3 months of 2,361,490.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
OREX is expected to report quarter earnings on February 25. The Biotechnology company’s earning per share consensus Street estimate stands at $0.03.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) is currently trading 25.58% below its 52-week-high, 87.14% above its 52-week-low. The 1-year range for the stock is $3.11 – $7.82. The stock price has underperformed the Nasdaq by 9.1%. OREX is currently valued at $0.72 billion and closed the last trading session at $5.82. The stock has a 50-day moving average of $5.51 and a 200-day moving average of $5.25.
Orexigen Therapeutics, Inc. (OREX) current short interest stands at 37.71 millions shares. It has increased by 2% from the same period of last month. Around 33% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.64 millions shares, the number of days required to cover the short positions stand at 23.1 days.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently eight analysts that cover OREX. Of those eight, eight have a Buy rating, . On a consensus basis this yields to a Buy rating. The consensus target price stands at $10.71.
A recent analyst activity consisted of RBC Capital Mkts who initiated their coverage on the stock with a Outperform rating on January 23. RBC Capital Mkts fixed their price target at $10. This corresponds to a 71.82% upside from the last closing price. On the date of report, the stock closed at $5.41.
Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system (CNS) disorders with an initial focus on obesity.